The Scientist

» FDA, developmental biology and culture

Most Recent

image: Book Excerpt from <em>An Essay on Science and Narcissism</em>

Book Excerpt from An Essay on Science and Narcissism

By | October 1, 2016

In Chapter 3, "Determining Narcissism in Science with Real-Life Examples," author Bruno Lemaitre considers Niels Jerne.

0 Comments

image: Church on the Late Show

Church on the Late Show

By | October 1, 2016

Harvard biologist George Church talks gene therapy, aging, and reviving the woolly mammoth with Stephen Colbert.

0 Comments

image: The Narcissistic Scientist

The Narcissistic Scientist

By | October 1, 2016

Are leading researchers driven more by the quest for knowledge or the pursuit of fame?

0 Comments

image: Thirty Years of Lab Safety

Thirty Years of Lab Safety

By | October 1, 2016

From mouth pipetting to automated liquid handling, life-science labs have gotten much safer over the past three decades.

0 Comments

image: Does Productivity Diminish Research Quality?

Does Productivity Diminish Research Quality?

By | September 28, 2016

More papers correlate with top-cited research for more-established academics, but not newly minted professors, according to a study.  

2 Comments

image: Q&A: From FDA to Industry

Q&A: From FDA to Industry

By | September 27, 2016

Among a subset of US Food and Drug Administration regulators who leave the agency, more than half go to work for pharmaceutical companies, researchers report.

1 Comment

image: Further Support for Early-Life Allergen Exposure

Further Support for Early-Life Allergen Exposure

By | September 20, 2016

Egg and peanut consumption during infancy is linked to lower risk of allergy to those foods later in life, according to a meta-analysis.

0 Comments

image: Feds Demand More Clinical Trial Reporting

Feds Demand More Clinical Trial Reporting

By | September 19, 2016

Expanded US Health and Human Services rules will require the results of more human studies to be made public.

1 Comment

image: Conditional FDA Approval for Fatal-Disease Drug

Conditional FDA Approval for Fatal-Disease Drug

By | September 19, 2016

The agency OKs Sarepta Therapeutics’s treatment for Duchenne muscular dystrophy through its accelerated approval pathway, which requires a confirmatory clinical trial.

0 Comments

Scientists estimate the risk to fetuses exposed to the virus in utero.

0 Comments

Popular Now

  1. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  2. Does Productivity Diminish Research Quality?
  3. How Plants Evolved Different Ways to Make Caffeine
  4. ESP on Trial
    Foundations ESP on Trial

    In the 1930s, parapsychologist Joseph Banks Rhine aimed to use scientific methods to confirm the existence of extrasensory perception, but faced criticisms of dubious analyses and irreproducible results.

RayBiotech